Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials

Wilfried Budach  Edwin Bölke  Christiane Matuschek

Department of Radiation Oncology, Heinrich Heine University of Düsseldorf, Germany

Introduction

One of the important advances in the treatment of breast cancer was the replacement of mastectomy by breast-conserving surgery followed by adjuvant radiotherapy as standard treatment of early breast cancer. Large clinical trials with a follow up of 20–30 years have shown that this treatment is oncologically safe for the patients and results in good to excellent cosmetic results in approximately 80% of patients [1–4]. Most patients in these trials received conventionally fractionated radiotherapy typically consisting of 25 fractions of 2 Gy administered over 5 consecutive weeks. Hypofractionated radiotherapy by definition uses a smaller number of fractions and doses per fraction above 2 Gy. Early experiences on hypofractionated radiotherapy were mainly available from post-mastectomy radiotherapy trials, and reported a high rate of quite devastating late radiation morbidity including severe fibrosis, plexopathy, and rib fractures [5–7]. In addition, experimental data indicated that most tumors, including breast cancer, exhibit a low fractionation sensitivity (high alpha/beta value) [8], whereas radiation-induced late normal tissue damage exhibits a high fractionation sensitivity (low alpha/beta value) [9]. Consequently, hypofractionated radiotherapy was thought to be harmful to patients and conventionally fractionated radiotherapy considered as standard of care in most countries [10, 11]. However, retrospective data indicated that the use of hypofractionated radiotherapy in 13–16 fractions using 2.5–3.3 Gy per fractions to decreased total doses of 39–43 Gy is not associated with high radiation-induced acute and late toxicity and seemed to result in local recurrence rates as low as those achieved with conventionally fractionated radiotherapy in the adjuvant setting [12–15]. These observations prompted research groups first from Ontario and later from the United Kingdom to compare adjuvant hypofractionated radiotherapy to adjuvant conventionally fractionated radiotherapy in preferentially early breast cancer. Potential benefits of hypofractionated radio-
therapy include improved convenience for the patients due to the lower number of radiotherapy sessions, less acute skin toxicity as a result of lower total doses, and lower costs for the healthcare system.

Patients and Methods

Randomized trials on adjuvant hypofractionated radiotherapy in breast cancer were detected by performing a Pubmed search using the terms ‘(hypofractionated or hypofractionation or fraction size)’ and ‘(radiotherapy or radiation or irradiation)’ and ‘breast cancer’ limited to ‘randomized controlled trial’. The search resulted in 21 hits. Considering only trials that had already published efficacy data and sufficient follow-up (> 5 years) yielded 4 trials [16–23] relevant for this review and meta-analysis of efficacy. These 4 randomized controlled trials tested different schedules of hypofractionated radiotherapy against conventionally fractionated radiotherapy (50 Gy in 25 fractions in 3–5 weeks). The expected effects of the different radiation schedules on normal tissues and tumor according to the prediction of the radiobiological linear quadratic model are illustrated in figure 1. The START Pilot [17, 18] and START A [22] trials compared conventionally fractionated radiotherapy each to 2 different 5-week schedules of hypofractionated radiotherapy in a 1:1:1 design, whereas in the Ontario trial [19, 20] and the START B trial [23], 3-week hypofractionated radiation schedules were compared to conventional fractionation in a 1:1 design. A consecutive conventionally fractionated boost radiotherapy to the tumor bed was administered in none of the patients in the Ontario trial and in 43–75% in the other trials. Further details of patients and treatments are provided in table 1. Overall, the distribution of breast cancer characteristics in the trials was quite typical for patients treated with breast-conserving surgery and adjuvant radiotherapy, with the exception of the Ontario trial in which node-positive patients were excluded. About 5% of all patients received a mastectomy, and approximately 8% received regional lymph node radiation. The primary end point of all trials was local tumor recurrence in the ipsilateral breast. Cosmetic outcome was assessed by consecutive photographs and self-assessment in the START trials and by the RTOG-EORTC Late Radiation Morbidity Scoring System in the Ontario trial. At the time of the latest reports, follow-up of approximately 10 years was completed in all trials. The risk of bias in the trials has already been assessed by a Cochrane systematic review [24] and attested a low risk or unclear risk of bias for the most relevant biases, indicating an overall satisfactory quality of the conduction and reporting of the trials. At the time of the Cochrane systematic review, follow-up of the START A and B trials was only 5 years. Outcome data with 10 years of follow-up have since been published [16]. This prompted us to perform a literature-based meta-analysis using the updated hazard ratios for the primary end point (ipsilateral breast cancer recurrence) of these trials from the published material and employing a commercial software package (MIX proTM, BiostatXL, Sunnyvale, CA, USA). For all other end points, no formal meta-analysis was performed.

Results

Effects of Hypofractionated Radiotherapy on Breast Cancer

None of the trials reported a significant difference in the ipsilateral breast recurrence rate for any of the tested hypofractionated radiation schedules. However, trends towards increased local relapse rates were observed in the 39 Gy in 13 fractions arms of the START Pilot trial and the START A trial (cumulative hazard ratio (HR) 1.26, 95% confidence interval (CI) 0.96–1.65; p = 0.096), whereas in all other hypofractionated schedules a tendency towards lower local relapse rates was detected (cumulative HR 0.86,

### Table 1. Treatment and patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Ontario</th>
<th>START Pilot</th>
<th>START A</th>
<th>START B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country</td>
<td>Canada</td>
<td>UK</td>
<td>UK</td>
<td>UK</td>
</tr>
<tr>
<td>patients</td>
<td>1234</td>
<td>1410</td>
<td>2236</td>
<td>2215</td>
</tr>
<tr>
<td>Mastectomy</td>
<td>0%</td>
<td>0%</td>
<td>15%</td>
<td>8%</td>
</tr>
<tr>
<td>Standard-RT</td>
<td>50 Gy/25 fx in 5 we.</td>
<td>50 Gy/25 fx in 5 we.</td>
<td>50 Gy/25 fx in 5 we.</td>
<td>50 Gy/25 fx in 5 we.</td>
</tr>
<tr>
<td>Hypofract. RT (1)</td>
<td>42.9 Gy/3.3 Gy</td>
<td>41.6 Gy/3.2 Gy</td>
<td>42.5 Gy/2.6 Gy</td>
<td>Ontario</td>
</tr>
<tr>
<td>Hypofract. RT (2)</td>
<td>42.9 Gy/3.3 Gy</td>
<td>41.6 Gy/3.3 Gy</td>
<td>42.5 Gy/2.6 Gy</td>
<td>Ontario</td>
</tr>
<tr>
<td>Boost-RT</td>
<td>74.5% (14 Gy/7 fx)</td>
<td>60.6% (10 Gy/5 fx)</td>
<td>42.6% (10 Gy/5 fx)</td>
<td>42.6% (10 Gy/5 fx)</td>
</tr>
<tr>
<td>Regional-RT</td>
<td>20.6%</td>
<td>14.2%</td>
<td>7.3%</td>
<td>3.7%</td>
</tr>
<tr>
<td>Mean age</td>
<td>50–59 years</td>
<td>54.5 years</td>
<td>57.2 years</td>
<td>57.4 years</td>
</tr>
<tr>
<td>LN positive</td>
<td>0%</td>
<td>32.7%</td>
<td>28.8%</td>
<td>22.8%</td>
</tr>
<tr>
<td>Tumor size &gt;=T2</td>
<td>20.0%</td>
<td>42.5%</td>
<td>48.6%</td>
<td>35.9%</td>
</tr>
<tr>
<td>Adjuvant CHX</td>
<td>11.0%</td>
<td>13.9%</td>
<td>35.5%</td>
<td>22.2%</td>
</tr>
</tbody>
</table>

RT = radiotherapy; fx = fractions; LN = lymph nodes; we. = weeks; CHX = chemotherapy; Ontario [19, 20], START Pilot [17, 18], START A [16, 22] and B [16, 23]
Effects of Hypofractionated Radiotherapy on Normal Tissues

Data on acute skin toxicity are available from the START A and B trials and cumulatively analyzed in a Cochrane review [24]. Although acute skin toxicity is mild in most patients regardless of the fractionation schedule used, the risk of a more pronounced skin reaction was considerably lower in the arms with hypofractionated radiotherapy (risk ratio 0.21, 95% CI 0.07–0.64; p = 0.0067). At the time of the publication of the Cochrane review, data on late radiation-induced toxicity and cosmetic results were not systematically available from the START A and B trials. Accordingly, the results of the Cochrane review that did not detect any significant difference in the overall incidence of late effects comparing the tested hypofractionated and conventionally fractionated radiation schedules have to be interpreted with caution. Since then, data on late radiation-induced effects have been published from all trials with a quite sufficient follow-up of 10 years. The results are summarized in the supplemental table (www.karger.com/DOI=439007). 39 Gy in 13 fractions administered within 5 weeks was tested in the START Pilot and START A trials, and induced significantly less late toxicity in both trials for most documented late effects. 43.9 Gy in 13 fractions within 5 weeks in the START Pilot trial was associated with a significantly higher frequency of marked changes in breast appearance and breast induration compared to conventional fractionation. This prompted the START trialists to lower the dose to 41.6 Gy in 13 fractions in START A. This latter regimen did not differ in terms of any documented late effects in comparison to conventionally fractionated radiotherapy (supplemental table; www.karger.com/DOI=439007). The same is true for the comparison of treatment arms using different end points in the Ontario trial. 40 Gy in 15 fractions administered as experimental arm of the START B trial proved to be significantly less toxic in terms of breast shrinkage, breast edema, and the development of telangiectasia at 10 years after treatment (supplemental table; www.karger.com/DOI=439007). The number of events for all other relevant late toxicities such as heart disease, rib fractures, lung toxicities, plexopathy, and development of second cancers was low in all arms of all trials, indicating no difference between hypofractionated and conventionally fractionated radiotherapy.

Table 2. Meta-analysis of randomized trials comparing hypofractionated radiotherapy to conventionally fractionated radiotherapy (fixed effects model)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Dose, Gy</th>
<th>HFX, weeks</th>
<th>HFX vs. CF, n</th>
<th>Recurr HFX at 10y, %</th>
<th>Recurr CF at 10y, %</th>
<th>HR</th>
<th>CL–</th>
<th>CL+</th>
<th>p</th>
<th>Weight, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>START Pilot [17]</td>
<td>42.9 vs. 50</td>
<td>5</td>
<td>466 vs. 470</td>
<td>9.6</td>
<td>12.1</td>
<td>0.86</td>
<td>0.57</td>
<td>1.30</td>
<td>0.47</td>
<td>17</td>
</tr>
<tr>
<td>START Pilot [17]</td>
<td>39 vs. 50</td>
<td>5</td>
<td>474 vs. 470</td>
<td>14.8</td>
<td>12.1</td>
<td>1.33</td>
<td>0.87</td>
<td>1.92</td>
<td>0.13</td>
<td>21</td>
</tr>
<tr>
<td>START A [23]</td>
<td>41.6 vs. 50</td>
<td>5</td>
<td>750 vs. 749</td>
<td>5.6</td>
<td>6.7</td>
<td>0.91</td>
<td>0.59</td>
<td>1.38</td>
<td>0.66</td>
<td>16</td>
</tr>
<tr>
<td>START A [23]</td>
<td>39 vs. 50</td>
<td>5</td>
<td>737 vs. 749</td>
<td>8.1</td>
<td>6.7</td>
<td>1.18</td>
<td>0.79</td>
<td>1.76</td>
<td>0.42</td>
<td>18</td>
</tr>
<tr>
<td>START B [23]</td>
<td>40 vs. 50</td>
<td>3</td>
<td>1,110 vs. 1,105</td>
<td>3.8</td>
<td>5.2</td>
<td>0.77</td>
<td>0.51</td>
<td>1.16</td>
<td>0.21</td>
<td>17</td>
</tr>
<tr>
<td>Ontario [19]</td>
<td>42.5 vs. 50</td>
<td>3</td>
<td>622 vs. 612</td>
<td>6.2</td>
<td>6.7</td>
<td>0.92</td>
<td>0.55</td>
<td>1.52</td>
<td>0.75</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>7,095</td>
<td>8.4</td>
<td>8.5</td>
<td>10.0</td>
<td>8.4</td>
<td>1.00</td>
<td>0.84</td>
<td>1.18</td>
<td>0.96</td>
<td>100</td>
</tr>
</tbody>
</table>

HFX = Hypofractionation; CF = conventional fractionation; Recurr = ipsilateral breast cancer recurrence; at 10y = after 10-year follow-up; HR = hazard ratio; CL– = lower 95% confidence limit of the HR; CL+ = upper 95% confidence limit of the HR.


Discussion

General

The results of the 4 large randomized trials comparing conventionally fractioned adjuvant radiotherapy (50 Gy/25 fractions in 5 weeks) in breast cancer to moderately hypofractionated radiotherapy with a reduction in the total dose by approximately 10% (39–42.9 Gy/13–16 fractions in 3–5 weeks) indicate that hypofractionated radiotherapy can be safely used in most breast cancer patients. Fears that hypofractionated radiotherapy could result in an unacceptably high rate of late radiation-induced toxicity were not confirmed [5–7]. The follow-up of 10 years in the trials is long enough to most likely exclude considerable changes in outcomes with longer follow-up. The late toxicity in the START trials may not have been evaluated with the optimal tools, but can be regarded as sufficient to exclude that relevant toxicities were not detected.

A detailed evaluation of the results indicates that not all tested hypofractionated regimens are equally suitable for clinical use. Although 39 Gy in 13 fractions was shown to be associated with less acute and late toxicity compared to conventionally fractionated radiotherapy, one has to keep in mind that a trend towards slightly increased ipsilateral breast cancer recurrences was observed in both trials (START Pilot and START A) testing this regimen. Consequently, 39 Gy in 13 fractions should not be preferentially used. The same applies for the use of 42.9 Gy in 13 fractions, since this schedule resulted in significantly increased late toxicity. The remaining schedules, 40 Gy in 15 fractions, 42.5 Gy in 16 fractions, and 41.6 Gy in 13 fractions, are all suitable for routine clinical use; however, the most favorable observations were reported for the START B regimen. 40 Gy administered in 15 fractions of 2.67 Gy within 3 weeks resulted in significantly less acute and late toxicity and was associated with a trend towards a lower rate of ipsilateral breast recurrence. In addition, a significantly reduced distant metastasis rate and significantly improved overall survival were reported from this regimen. Although the START trialists themselves do not claim a causal relationship between the use of hypofractionation and the observation of a lower distant metastasis rate and improved survival [16], in view of no significant differences in local tumor control and no trend towards the same relationship in the similarly designed Ontario trial [19] one cannot entirely exclude a beneficial effect as the result of the substantially shorter overall radiotherapy treatment time. Since the 3-week schedule is also more convenient for most patients, the START B regimen should be the preferred schedule.

The question arises whether hypofractionated radiotherapy should be used as the preferred schedule for adjuvant radiotherapy in all breast cancer patients. Patients below 40 years, with locally advanced breast cancer, and those having undergone mastectomy were not well represented in the hypofractionation trials. Consequently, some national treatment guidelines do not recommend hypofractionated radiotherapy for these patients [26–28], whereas others do [29]. From a radiobiological point of view, it is unlikely that hypofractionated radiotherapy in younger patients or patients after mastectomy or those with locally advanced cancer would result in substantially different outcomes.

Chemotherapy

Adjuvant chemotherapy was administered in approximately 1,600 patients in the hypofractionation trials. Subgroup analyses from the START A and B [16] trials did not give any indication that hypofractionation should not be employed if adjuvant chemotherapy is given. None of the patients in the trials on hypofractionated radiotherapy received neoadjuvant chemotherapy. Whether the use of hypofractionated radiotherapy after neoadjuvant chemotherapy is safe for the patients, is formally unknown, and it is therefore not generally recommended in this situation. However, no substantial change in the fractionation sensitivity of tumors and normal tissues induced by chemotherapy was observed in both experimental and clinical data [30, 31] indicating that hypofractionated radiotherapy is probably also safe in this clinical setting. Further well documented clinical observations are needed to confirm the safety of hypofractionation after neoadjuvant chemotherapy.

Anti-HER2 Therapy

Trastuzumab and other drugs targeting the HER2 receptor were not clinically available during the accrual time of the trials on hypofractionated radiotherapy. Trastuzumab can be safely used after or concurrently with conventionally fractionated radiotherapy after breast-conserving surgery or mastectomy [32] at least if no radiotherapy for the treatment of the internal mammary chain lymph nodes is administered. In the palliative setting, trastuzumab was administered in combination with hypofractionated radiotherapy in different clinical situations [33–35]. No relevantly enhanced acute or late toxicity has been reported. Keeping in mind the limited long-term follow-up in the palliative setting and the lack of data with hypofractionated radiotherapy in combination with trastuzumab in the curative setting, cautious use of hypofractionated radiotherapy is appropriate before data on long-term outcome are available.

Regional Radiotherapy and Cardiac Toxicity

Radiotherapy to the supra/infrACLavicular and axillary regional lymph nodes was administered in 583 patients in the hypofractionated arms of the 4 randomized trials. Shoulder stiffness and edema of the arm were not more frequently reported after hypofractionated radiotherapy compared to conventionally fractionated radiotherapy (table 3 a and b). 1 case of brachial plexopathy was reported after 41.6 Gy in 13 fractions out of 211 treated patients in the START A trial. Keeping in mind that brachial plexopathy may manifest itself as late as 30 years after radiotherapy and that at 10 years approximately 75% of the final incidence of plexopathy is reached [6], one can calculate the worst case upper 95% confidence limits for plexopathy at 30 year after hypofractionated radiotherapy at < 6% for the START A and < 8% for the START B regimens. Although it is unlikely that these worst-case-scenario incidences will ever be observed, hypofractionated radiotherapy of the supra/infrACLavicular lymph nodes should be used with caution before further evidence is available. If used in the current situation, the 40 Gy in 15 fractions regimen should be preferred, and overdosing at the brachial plexus structures should be avoided. No long-term
data is available on hypofractionated radiotherapy to the internal mammary chain lymph nodes. The low doses and volumes applied with typical tangential radiotherapy after breast-conserving surgery or mastectomy as used in hypofractionation trials were not associated with any evidence of more frequent heart toxicity in the hypofractionated arm of the trials. As visualized in figure 1, using the 40 Gy in 15 fractions regimen, fractionation sensitivities for heart and lungs have to be assumed equivalent to alpha/beta ratios of below 0.75 Gy to predict more harmful effects of hypofractionation compared to conventional fractionation. The current knowledge [36, 37] suggests higher alpha/beta ratios for heart and lungs indicating that hypofractionation is in theory save. However, this has to be substantiated by clinical data, especially since many breast cancer patients receive potentially cardiotoxic drugs such as anthracyclines and trastuzumab.

**Large Breasts**

Radiotherapy of large breasts (> 1,800 ml) results in a larger dose inhomogeneity compared to smaller breast. Consequently, the risk of an overdose to some parts of the breast volume is higher in large breasts. The question arises whether this overdose is more critical if hypofractionated radiotherapy is used. Models (not shown) of overdoses using the 40 Gy in 15 fractions regimen, fractionation sensitivities for heart and lungs have to be assumed equivalent to alpha/beta ratios of below 0.75 Gy to predict more harmful effects of hypofractionation compared to conventional fractionation. The current knowledge [36, 37] suggests higher alpha/beta ratios for heart and lungs indicating that hypofractionation is in theory save. However, this has to be substantiated by clinical data, especially since many breast cancer patients receive potentially cardiotoxic drugs such as anthracyclines and trastuzumab.

<table>
<thead>
<tr>
<th>Age</th>
<th>Specific Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 40 years</td>
<td>conventional RT (25–28 fractions) with integrated or sequential boost</td>
</tr>
<tr>
<td>40–65 years</td>
<td>conventional RT with integrated or sequential boost, or hypofractionated RT with sequential boost</td>
</tr>
<tr>
<td>&gt; 65 years</td>
<td>low risk: consider hypofractionated RT without boost (15–16 fractions)</td>
</tr>
<tr>
<td></td>
<td>high risk: RT as for 40–65 years; in elderly patients individual counseling including omission of radiotherapy according to individual risk after geriatric assessment</td>
</tr>
<tr>
<td>Any age</td>
<td>if radiotherapy of the regional lymph nodes is included, conventionally fractionated RT (25–28 fractions)</td>
</tr>
</tbody>
</table>

**Conclusion**

In conclusion, moderately hypofractionated radiotherapy using schedules such as 40 Gy in 15 fractions administered within 3 weeks has been shown to be as efficient and safe as conventionally fractionated radiotherapy for most breast cancer patients who need adjuvant radiotherapy after breast-conserving surgery. In patients younger than 40 years, after neoadjuvant chemotherapy, and if regional lymph node radiotherapy is needed, caution is still recommended. The AGO (German Gynecological Oncology Working Group) and the DEGRO (German Society for Radiotherapy and Oncology) recently published a consensus guideline for the use of hypofractionated radiotherapy in breast cancer, which is summarized in table 3.

**Supplemental Material**

**Supplemental Table.** Late effects

To access the supplemental table, please refer to [www.karger.com](http://www.karger.com/). DOI: 439007.

**Disclosure Statement**

The authors have no conflict of interest to declare.
References

1 Littere S, Wersustky G, Fentiman IS, et al.: Breast con- 
servation therapy versus mastectomy for stage I-II breast 
2 Fisher B, Anderson S, Bryant J, et al.: Twenty-year fol-
low-up of a randomized trial comparing total mastec-
tomy, lumpectomy, and lumpectomy plus irradiation for 
3 Jacobson JA, Danforth DN, Cowan KH, et al.: Ten-
year results of a comparison of conservation with mas-
tectomy in the treatment of stage I and II breast can-
4 Darby S, McGale P, Correa C, et al.; Early Breast Can-
cer Trialists’ Collaborative Group: Effect of radiother-
apy after breast-conserving surgery on 10-year recur-
rence and 15-year breast cancer death: meta-analysis of 
individual patient data for 10,801 women in 17 ran-
5 Overgaard M, Bentzen SM, Christensen JI, Madsen 
EH: The value of the NSD formula in equation of acute 
and late radiation complications in normal tissue fol-
lowing 2 and 5 fractions per week in breast cancer pa-
tients treated with postmastectomy irradiation. Radio-
ther Oncol 1987;9:1–11.
6 Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska 
M, et al.: Radiation-induced brachial plexopathy and 
hypofractionated regimens in adjuvant irradiation of 
patients with breast cancer—a review. Acta Oncol 2006; 
45:260–284.
7 Overgaard M: Spontaneous radiation-induced rib frac-
tions in breast cancer patients treated with postmastec-
tomy irradiation. A clinical radiobiological analysis of 
the influence of fraction size and dose-response rela-
tionships on late bone damage. Acta Oncol 1988;27: 
117–122.
8 Stuschke M, Budach V, Sack H: Radiosensitivity of 
human glioma, sarcoma, and breast cancer spher-
oids depends on tumor differentiation. Int J Radiat 
9 Van Limbergen E, Rijnders A, van der Schueren E, et 
al.: Cosmetic evaluation of breast conserving treatment 
for mammary cancer. 2. A quantitative analysis of the 
influence of radiation dose, fractionation schedules 
and surgical treatment techniques on cosmetic results. 
10 Yamada Y, Ackerman J, Fransen E, et al.: Does the dose 
and fractionation schedule influence local control of 
adjuvant radiotherapy for early stage breast cancer? Int J 
11 Fletcher GH: Hypofractionation: lessons from compli-
12 Clark RM, Wellen T, Levine M, et al.: Randomized clinical 
trial of breast irradiation following lumpec-
tomy and axillary dissection for node-negative breast 
13 Ash DV, Benson EA, Sainsbury JR, et al.: Seven-year 
follow-up on 334 patients treated by breast conserving 
surgery and short course radical postoperative radio-
therapy: a report of the Yorkshire Breast Cancer 
14 Olivotto IA, Weir LM, et al.: Late cosmetic results of 
short fractionation for breast conservation. Radiother 
fractionation schedule for postlumpectomy breast can-
cer patients. Int J Radiat Oncol Biol Phys 2000;47: 
1219–1228.
16 Haviland JS, Owen JR, Dewar JA, et al.: The UK Stand-
ardisation of Breast Radiotherapy (START) trials of 
radiotherapy hypofractionation for treatment of early 
breast cancer: 10-year follow-up results of two ran-
domised controlled trials. Lancet Oncol 2013;14:1086– 
1094.
17 Owen JR, Ashton A, Bliss JM, et al.: Effect of radio-
therapy fraction size on tumour control in patients 
with early-stage breast cancer after local tumour exci-
sion: long-term results of a randomised trial. Lancet 
2006;7:467–471.
18 Yarnold J, Ashton A, Bliss J, et al.: Fractionation sensi-
tivity and dose response of late adverse effects in the 
breast after radiotherapy for early breast cancer: long-
term results of a randomised trial. Radiother Oncol 
results of hypofractionated radiation therapy for breast 
trial of breast irradiation schedules after lumpectomy 
for women with lymph node-negative breast cancer. 
21 Yarnold J, Bentzen SM, Coles C, Haviland J: Hypofrac-
tionated whole-breast radiotherapy for women with 
early breast cancer: myths and realities. Int J Radiat 
22 Group ST, Bentzen SM, Agrawal RK, et al.: The UK 
Standardisation of Breast Radiotherapy (START) Trial 
of radiotherapy hypofractionation for treatment of 
early breast cancer: a randomised trial. Lancet 
23 Group ST, Bentzen SM, Agrawal RK, et al.: The UK 
Standardisation of Breast Radiotherapy (START) Trial 
of radiotherapy hypofractionation for treatment of 
early breast cancer: a randomised trial. Lancet 
24 James ML, Lehman M, Hider PN, et al.: Fraction size 
in radiation treatment for breast conservation in early 
CD003860.
25 Bane AL, Whelan TJ, Pond GR, et al.: Tumor factors 
predictive of response to hypofractionated radiother-
apy in a randomized trial following breast conserving 
26 Sedlmayer F, Sautter-Bihl ML, Budach W, et al.: DEGRO 
practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving 
therapy for invasive breast cancer. Strahlenther Onkol 
2013;189:825–833.
27 Senkus E, Kyrilides S, Penault-Llorca F, et al.: Pri-
mary breast cancer: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up. Ann Oncol 
2013;24(suppl 6):vi7–23.
28 Besnard S, Cutuli B, Fourquet A, et al.; French Na-
tional Cancer Institute: (Radiotherapy of invasive 
breast cancer: French national guidelines). Cancer 
29 Breast cancer Dutch Guideline, version 2.0. www.onco-
line.nl/uploaded/docs/mammacarcinoom/Dutch%20 
Breast%20Cancer%20Guideline%202012.pdf
30 Van Rongen E, Kuipers WC, Baten-Wittwer A: The 
influence of platinum drugs on the radiation response 
31 Collette S, Collette L, Buddiharto T, et al.: Predictors of 
the risk of fibrosis at 10 years after breast conserving 
therapy for early breast cancer: a study based on the 
EORTC Trial 22881–10882 ‘boost versus no boost’. Eur J 
32 Halyard MY, Psansky TM, Dueck AC, et al.: Radio-
therapy and adjuvant trastuzumab in operable breast 
cancer: tolerability and adverse event data from the 
NCCGT Phase III Trial N9831. J Clin Oncol 2009;27: 
2638–2644.
33 Farolfi A: The impact of radiotherapy, trastuzumab 
and hormonal therapy on cardiac fibrosis. More is 
34 Riemer AR, Zielinski CC. (Use of trastuzumab in the 
222.
35 Jeyakumar A, Younis T: Trastuzumab for HER2-pos-
tive metastatic breast cancer: clinical and economic 
187.
36 Gagliardi G, Constinte LS, Moisienko V, et al.: Radia-
tion dose–volume effects in the heart. Int J Radiat 
Oncol Biol Phys 2010;76(3 suppl):S70–S83.
37 Marks LB, Bentzen SM, Deasy JO, et al.: Radiation 
dose–volume effects in the lung. Int J Radiat Oncol 
Biol Phys 2010;76(3 suppl):S70–S76.
38 Della K, Vonthein R, Zimmer J, et al.; ARO Study 
Group: Hypofractionation with simultaneous inte-
grated boost for early breast cancer: results of the Ger-
man multicenter phase II trial (ARO-2010–01). Strahl-
enther Onkol 2014;190:646–653.
of the randomised UK FAST Trial of radiotherapy 
hypofractionation for treatment of early breast cancer 
(CRUKE/04/015). Radiother Oncol 2011;100:93–100.

Hypofractionated Radiotherapy in Breast Cancer

Breast Care 2015;10:240–245

245

Downloaded by: 54.70.40.11 - 11/26/2017 8:26:21 AM